Related Experiment Video
Updated: Feb 18, 2026
05:27
Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
Published on: June 16, 2023
2.4K
LncRNA expression and implication in osteosarcoma: a systematic review and meta-analysis
Ying Wang1,2, Yuelong Huang2, Peng Xiang3
1Department of Molecular Orthopaedics, Beijing Institute of Traumatology and Orthopaedics.
Oncotargets and Therapy
|November 30, 2017
Summary
Abnormally expressed long noncoding RNAs (lncRNAs) significantly impact osteosarcoma patient survival. These lncRNAs show potential as biomarkers for predicting clinical outcomes and guiding chemotherapy strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Osteosarcoma, a primary bone cancer, has poor survival rates.
- Aberrant expression of long noncoding RNAs (lncRNAs) is observed in osteosarcoma.
- lncRNAs are potential prognostic markers for osteosarcoma.
Purpose of the Study:
- To systematically evaluate the prognostic value of four specific lncRNAs (TUG1, UCA1, BCAR4, HULC) in osteosarcoma.
- To assess the association between lncRNA expression and overall survival (OS) in osteosarcoma patients.
Main Methods:
- A meta-analysis was conducted on eligible articles.
- Systematic literature search performed in PubMed, Web of Science, Embase, and Elsevier ScienceDirect.
- Survival outcomes analyzed by OS, with subgroup analyses performed.
Main Results:
- 1,361 osteosarcoma patients and 12 lncRNAs from 16 articles were included.
- High expression of 10 lncRNAs correlated with worse survival outcomes.
- Two lncRNAs positively affected patients' overall survival.
Conclusions:
- Abnormally expressed lncRNAs significantly influence osteosarcoma patient survival.
- Combined lncRNAs may serve as novel biomarkers for clinical outcomes.
- lncRNAs could aid in selecting adjuvant chemotherapy strategies.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
02:39lncRNA - Long Non-coding RNAs
3.7K
3.7K
02:55The Nucleolus
10.5K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.5K
03:03mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K